Clairity, a breast imaging AI startup, secured $43M to advance its FDA-cleared mammogram risk prediction tool.
Key Details
- 1Clairity, founded in 2020 by radiologist Dr. Constance Lehman, raised $43 million in Series B funding.
- 2Major investors include Ace Global Equity, Santé Ventures, and the Breast Cancer Research Foundation.
- 3The AI tool predicts five-year breast cancer risk from routine mammograms.
- 4Clairity Breast received FDA de novo authorization in May 2024.
- 5The funds will support commercialization and expanding partnerships.
Why It Matters
This funding enables broader access to AI-driven breast cancer risk prediction using standard mammography, potentially improving early detection and risk stratification. Widespread adoption could reshape preventive strategies and workflow in breast imaging practices.
Source
Radiology Business
Related News
•Radiology Business
a2z Radiology Raises $5M, Lands FDA Clearance for Multi-Condition CT AI
Boston-based a2z Radiology raised $4.5M and earned FDA clearance for its Unified Triage AI solution for abdominal and pelvic CT scans.
•AuntMinnie
AI Ultrasound Tool May Cut Unnecessary Breast Biopsies by 60%
An FDA-cleared AI tool for breast ultrasound may reduce unnecessary biopsies of benign breast lesions by about 60%.
•AuntMinnie
AI Model Using Mammograms Enhances Five-Year Breast Cancer Risk Assessment
A new image-only AI model more accurately predicts five-year breast cancer risk than breast density alone, according to multinational research presented at RSNA 2025.